📰 Lantern Pharma News
Page 2 - Lantern Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lantern Pharma. Real-time updates on events, politics, business and more.
March 11, 2024
Webcast to be held Monday, March 18th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. ...
February 15, 2024
Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC. The...
February 15, 2024
Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC.The cryptophycin ADC has shown picomolar potency in a wide range of solid tumors tested in preclinical development and is being furthe...
January 17, 2024
Starlight Therapeutics— a Lantern Pharma subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective...
December 20, 2023
Preclinical data showed that LP-184 shrunk tumors in vivo by more than 90% in just 8 weeks.
December 5, 2023
The FDA has granted orphan drug designation to LP-284 for use in the treatment of patients with high-grade B-cell lymphoma harboring MYC and BCL2 rearrangements.
December 5, 2023
Currently, there is no established standard of care treatment approach of HGBL, with frontline interventions consisting of chemo-immunotherapies.
November 30, 2023
The Orphan Drug Designation strengthens LP-284’s clinical development path and can provide for additional market exclusivity and commercial protection. Lantern has initiated a first-in-human...
November 30, 2023
Lantern Pharma Inc. (LTRN) announced the FDA has granted LP-284 Orphan Drug Designation for the treatment of high-grade B-cell lymphoma with MYC and BCL2 rearrangements.